• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《2020 年肠型贝赫切特病循证诊断与临床实践指南》,特发性疾病,健康与劳动科学研究补助金编辑。

Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.

机构信息

Department of Intestinal Inflammation Research, Hyogo College of Medicine, Hyogo, Japan.

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.

出版信息

J Gastroenterol. 2020 Jul;55(7):679-700. doi: 10.1007/s00535-020-01690-y. Epub 2020 May 7.

DOI:10.1007/s00535-020-01690-y
PMID:32377946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7297851/
Abstract

Behçet's disease (BD) is an intractable systemic inflammatory disease characterized by four main symptoms: oral and genital ulcers and ocular and cutaneous involvement. The Japanese diagnostic criteria of BD classify intestinal BD as a specific disease type. Volcano-shaped ulcers in the ileocecum are a typical finding of intestinal BD, and punched-out ulcers can be observed in the intestine or esophagus. Tumor necrosis factor inhibitors were first approved for the treatment of intestinal BD in Japan and have been used as standard therapy. In 2007 and 2014, the Japan consensus statement for the diagnosis and management of intestinal BD was established. Recently, evidence-based JSBD (Japanese Society for BD) Clinical Practice Guidelines for BD (Japanese edition) were published, and the section on intestinal BD was planned to be published in English. Twenty-eight important clinical questions (CQs) for diagnosis (CQs 1-6), prognosis (CQ 7), monitoring and treatment goals (CQs 8-11), medical management and general statement (CQs 12-13), medical treatment (CQs 14-22), and surgical treatment (CQs 23-25) of BD and some specific situations (CQs 26-28) were selected as unified consensus by the members of committee. The statements and comments were made following a search of published scientific evidence. Subsequently, the levels of recommendation were evaluated based on clinical practice guidelines in the Medical Information Network Distribution Service. The degree of agreement was calculated using anonymous voting. We also determined algorithms for diagnostic and therapeutic approaches for intestinal BD. The present guidelines will facilitate decision making in clinical practice.

摘要

贝赫切特病(BD)是一种难以治愈的全身性炎症性疾病,其特征为四大主要症状:口腔和生殖器溃疡、眼部和皮肤损伤。日本 BD 的诊断标准将肠型 BD 归类为一种特殊的疾病类型。回盲部的火山口样溃疡是肠型 BD 的典型表现,也可在肠道或食管观察到穿孔样溃疡。肿瘤坏死因子抑制剂最初在日本被批准用于治疗肠型 BD,并已被用作标准治疗。2007 年和 2014 年,日本制定了肠型 BD 的诊断和管理共识声明。最近,基于循证的日本 BD 学会(JSBD)BD 临床实践指南(日本版)发布,肠型 BD 部分计划以英文发表。选择了 28 个与 BD 的诊断(问题 1-6)、预后(问题 7)、监测和治疗目标(问题 8-11)、医疗管理和总体陈述(问题 12-13)、药物治疗(问题 14-22)和手术治疗(问题 23-25)以及一些特殊情况(问题 26-28)相关的重要临床问题(CQs)作为委员会成员的统一共识。根据发表的科学证据,对声明和评论进行了检索。随后,根据医疗信息网络分发服务中的临床实践指南评估了推荐的等级。使用匿名投票计算了一致性程度。我们还确定了肠型 BD 的诊断和治疗方法的算法。本指南将有助于临床实践中的决策制定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/7297851/a0055d2d18ae/535_2020_1690_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/7297851/56778d9fa355/535_2020_1690_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/7297851/9ab0c0f6b4b7/535_2020_1690_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/7297851/a0055d2d18ae/535_2020_1690_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/7297851/56778d9fa355/535_2020_1690_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/7297851/9ab0c0f6b4b7/535_2020_1690_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/7297851/a0055d2d18ae/535_2020_1690_Fig3_HTML.jpg

相似文献

1
Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants.《2020 年肠型贝赫切特病循证诊断与临床实践指南》,特发性疾病,健康与劳动科学研究补助金编辑。
J Gastroenterol. 2020 Jul;55(7):679-700. doi: 10.1007/s00535-020-01690-y. Epub 2020 May 7.
2
Diagnosis and management of intestinal Behçet's disease.肠道白塞病的诊断与管理
Clin J Gastroenterol. 2014 Jun;7(3):205-12. doi: 10.1007/s12328-014-0488-0. Epub 2014 Apr 20.
3
Recommendations for the management of the vascular involvement in Behçet's disease by the Japanese National Research Committee for Behçet's disease-secondary publication.日本贝切特病国家研究委员会关于贝切特病血管病变管理的建议——二次出版物。
Mod Rheumatol. 2023 Dec 22;34(1):182-193. doi: 10.1093/mr/road002.
4
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.肠白塞病诊断与管理的共识意见(第 2 版):抗 TNFα 单克隆抗体的适应证。
J Gastroenterol. 2014 Jan;49(1):156-62. doi: 10.1007/s00535-013-0872-4. Epub 2013 Aug 18.
5
Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach.采用改良德尔菲法制定肠道白塞病诊断与管理的共识声明。
J Gastroenterol. 2007 Sep;42(9):737-45. doi: 10.1007/s00535-007-2090-4. Epub 2007 Sep 25.
6
Outcome predictors for intestinal Behçet's disease.肠型贝赫切特病的预后预测因子。
Yonsei Med J. 2013 Sep;54(5):1084-90. doi: 10.3349/ymj.2013.54.5.1084.
7
Recommendations for the Management of Neuro-Behçet's Disease by the Japanese National Research Committee for Behçet's Disease.日本贝赫切特病国家研究委员会关于神经贝赫切特病的管理建议。
Intern Med. 2020 Oct 1;59(19):2359-2367. doi: 10.2169/internalmedicine.4705-20. Epub 2020 Jun 30.
8
Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.成功使用Vedolizumab 治疗有肿瘤病史的难治性肠白塞病:病例报告及文献复习。
Front Immunol. 2023 May 23;14:1205046. doi: 10.3389/fimmu.2023.1205046. eCollection 2023.
9
Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea.肠道白塞病的长期临床结局:韩国一家三级医院的30年队列研究。
J Gastroenterol Hepatol. 2023 Mar;38(3):386-392. doi: 10.1111/jgh.16056. Epub 2022 Nov 21.
10
Updated treatment strategies for intestinal Behçet's disease.肠道白塞病的更新治疗策略。
Korean J Intern Med. 2018 Jan;33(1):1-19. doi: 10.3904/kjim.2017.377. Epub 2017 Dec 8.

引用本文的文献

1
Predictors of anti-TNF treatment failure in intestinal Behçet's disease: a multicenter retrospective cohort study.肠道白塞病抗TNF治疗失败的预测因素:一项多中心回顾性队列研究
Clin Rheumatol. 2025 Jul 16. doi: 10.1007/s10067-025-07581-y.
2
Assessment of IL-6 Pathway Inhibition in Gastrointestinal Behçet's Disease from Immunological and Clinical Perspectives.从免疫学和临床角度评估白细胞介素-6通路抑制在胃肠道白塞病中的作用
Biomedicines. 2025 Jan 20;13(1):247. doi: 10.3390/biomedicines13010247.
3
Specific plasma metabolite profile in intestinal Behçet's syndrome.

本文引用的文献

1
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.NUDT15 基因变异与炎症性肠病患者硫嘌呤诱导的骨髓抑制相关。
JAMA. 2019 Feb 26;321(8):773-785. doi: 10.1001/jama.2019.0709.
2
Differentiation between intestinal Behçet’s disease and Crohn’sdisease based on endoscopy.基于内镜的肠型贝赫切特病与克罗恩病的鉴别。
Turk J Med Sci. 2019 Feb 11;49(1):42-49. doi: 10.3906/sag-1807-67.
3
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
肠道白塞病的特定血浆代谢物谱。
Orphanet J Rare Dis. 2025 Jan 13;20(1):21. doi: 10.1186/s13023-024-03484-4.
4
Behçet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan.白塞病:日本的发病率、患病率及生物制剂使用的真实世界数据。
J Gastroenterol. 2025 Mar;60(3):294-305. doi: 10.1007/s00535-024-02191-y. Epub 2024 Dec 6.
5
Intestinal ultrasound for intestinal Behçet disease reflects endoscopic activity and histopathological findings.肠道超声检查对肠道白塞病的诊断可反映内镜下活动情况及组织病理学表现。
Intest Res. 2024 Jul;22(3):297-309. doi: 10.5217/ir.2023.00129. Epub 2024 Jul 16.
6
miR-141-3p attenuates RSL3-induced ferroptosis and intestinal epithelial-mesenchymal transition via directly inhabits ZEB1 in intestinal Behçet's syndrome.miR-141-3p 通过直接抑制肠道白塞综合征中的 ZEB1 来减轻 RSL3 诱导的铁死亡和肠上皮-间充质转化。
Clin Rheumatol. 2024 Jul;43(7):2273-2285. doi: 10.1007/s10067-024-07007-1. Epub 2024 May 20.
7
Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study.肠道白塞病合并骨髓增生异常综合征的最佳治疗方法:KASID和KSBD多中心研究
Yonsei Med J. 2024 May;65(5):265-275. doi: 10.3349/ymj.2023.0321.
8
Refractory Intestinal Behçet-Like Disease Associated with Trisomy 8 Myelodysplastic Syndrome Resolved by Parenteral Nutrition.与8号染色体三体骨髓增生异常综合征相关的难治性肠白塞氏病样疾病经肠外营养治愈
Case Rep Gastroenterol. 2023 Oct 11;17(1):287-293. doi: 10.1159/000533578. eCollection 2023 Jan-Dec.
9
Advances in Management of Intestinal Behçet's Disease: A Perspective From Gastroenterologists.肠道白塞病的管理进展:胃肠病学家的观点
J Rheum Dis. 2021 Jan 1;28(1):4-16. doi: 10.4078/jrd.2021.28.1.4.
10
Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.儿童贝赫切特病的生物药物治疗:已发表数据的综合分析。
BioDrugs. 2023 Nov;37(6):813-828. doi: 10.1007/s40259-023-00613-6. Epub 2023 Jun 29.
NUDT15 密码子 139 是预测日本炎症性肠病患者巯嘌呤诱导的严重不良事件的最佳药物遗传学标志物:一项多中心研究。
J Gastroenterol. 2018 Sep;53(9):1065-1078. doi: 10.1007/s00535-018-1486-7. Epub 2018 Jun 19.
4
HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.HLA-DQA1-HLA-DRB1 多态性是炎症性肠病患者硫唑嘌呤诱导胰腺炎的主要预测因子。
Aliment Pharmacol Ther. 2018 Mar;47(5):615-620. doi: 10.1111/apt.14483. Epub 2017 Dec 22.
5
Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.英夫利昔单抗治疗白塞病肠道、神经及血管受累:一项多中心、前瞻性、开放标签、单臂3期研究中的疗效、安全性及药代动力学
Medicine (Baltimore). 2016 Jun;95(24):e3863. doi: 10.1097/MD.0000000000003863.
6
Behçet's disease in children, an overview.儿童贝赫切特病概述
Pediatr Rheumatol Online J. 2016 Feb 18;14(1):10. doi: 10.1186/s12969-016-0070-z.
7
Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD.儿科贝赫切特病的共识分类标准:PEDBD。
Ann Rheum Dis. 2016 Jun;75(6):958-64. doi: 10.1136/annrheumdis-2015-208491. Epub 2015 Dec 23.
8
NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.在日本炎症性肠病患者中,NUDT15 R139C相关的硫嘌呤白细胞减少症是由6-硫鸟嘌呤核苷酸非依赖性机制介导的。
J Gastroenterol. 2016 Jan;51(1):22-9. doi: 10.1007/s00535-015-1142-4. Epub 2015 Nov 21.
9
A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter.一种由编码前列腺素转运体的SLCO2A1基因突变引起的遗传性肠病。
PLoS Genet. 2015 Nov 5;11(11):e1005581. doi: 10.1371/journal.pgen.1005581. eCollection 2015 Nov.
10
Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease.硫唑嘌呤对肠道白塞病患者的术后影响
Dig Dis Sci. 2015 Dec;60(12):3721-7. doi: 10.1007/s10620-015-3799-1. Epub 2015 Jul 22.